Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force
- PMID: 37338868
- DOI: 10.1001/jama.2023.6369
Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force
Abstract
Importance: Anxiety is commonly seen in primary care and associated with substantial burden.
Objective: To review the benefits and harms of screening and treatment for anxiety and the accuracy of instruments to detect anxiety among primary care patients.
Data sources: MEDLINE, PsychINFO, Cochrane library through September 7, 2022; references of existing reviews; ongoing surveillance for relevant literature through November 25, 2022.
Study selection: English-language original studies and systematic reviews of screening or treatment compared with control conditions and test accuracy studies of a priori-selected screening instruments were included. Two investigators independently reviewed abstracts and full-text articles for inclusion. Two investigators independently rated study quality.
Data extraction and synthesis: One investigator abstracted data; a second checked accuracy. Meta-analysis results were included from existing systematic reviews where available; meta-analyses were conducted on original research when evidence was sufficient.
Main outcomes and measures: Anxiety and depression outcomes; global quality of life and functioning; sensitivity and specificity of screening tools.
Results: Of the 59 publications included, 40 were original studies (N = 275 489) and 19 were systematic reviews (including ≈483 studies [N≈81 507]). Two screening studies found no benefit for screening for anxiety. Among test accuracy studies, only the Generalized Anxiety Disorder (GAD) GAD-2 and GAD-7 screening instruments were evaluated by more than 1 study. Both screening instruments had adequate accuracy for detecting generalized anxiety disorder (eg, across 3 studies the GAD-7 at a cutoff of 10 had a pooled sensitivity of 0.79 [95% CI, 0.69 to 0.94] and specificity of 0.89 [95% CI, 0.83 to 0.94]). Evidence was limited for other instruments and other anxiety disorders. A large body of evidence supported the benefit of treatment for anxiety. For example, psychological interventions were associated with a small pooled standardized mean difference of -0.41 in anxiety symptom severity in primary care patients with anxiety (95% CI, -0.58 to -0.23]; 10 RCTs [n = 2075]; I2 = 40.2%); larger effects were found in general adult populations.
Conclusions and relevance: Evidence was insufficient to draw conclusions about the benefits or harms of anxiety screening programs. However, clear evidence exists that treatment for anxiety is beneficial, and more limited evidence indicates that some anxiety screening instruments have acceptable accuracy to detect generalized anxiety disorder.
Comment in
-
Are There Reasons to Fear Anxiety Screening?JAMA. 2023 Jun 27;329(24):2132-2134. doi: 10.1001/jama.2023.7239. JAMA. 2023. PMID: 37338897 No abstract available.
Similar articles
-
Screening for Depression, Anxiety, and Suicide Risk in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Jun. Report No.: 22-05295-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2023 Jun. Report No.: 22-05295-EF-1. PMID: 37406149 Free Books & Documents. Review.
-
Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents: An Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Oct. Report No.: 22-05293-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Oct. Report No.: 22-05293-EF-1. PMID: 36282939 Free Books & Documents. Review.
-
Depression and Suicide Risk Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2023 Jun 20;329(23):2068-2085. doi: 10.1001/jama.2023.7787. JAMA. 2023. PMID: 37338873
-
Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Feb. Report No.: 19-05257-EF-1. PMID: 32129963 Free Books & Documents. Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
Cited by
-
What is the role of screening instruments in the management of psychiatric comorbidities in epilepsy? Tools and practical tips for the most common comorbidities: Depression and anxiety.Epilepsy Behav Rep. 2024 Feb 14;25:100654. doi: 10.1016/j.ebr.2024.100654. eCollection 2024. Epilepsy Behav Rep. 2024. PMID: 38389991 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
